When someone is diagnosed with amyotrophic lateral sclerosis (ALS), the world changes in an instant. It’s not just a diagnosis-it’s a countdown. ALS, also known as Lou Gehrig’s disease, attacks the nerve cells that control your muscles. These cells, called motor neurons, start dying. At first, you might notice a weak grip, trouble climbing stairs, or slurred speech. Then, over months or years, those symptoms get worse. Muscles weaken. Paralysis spreads. Breathing becomes harder. Most people live only 3 to 5 years after symptoms begin. There’s no cure. But there is riluzole-one of the few tools we have to slow it down.
How ALS Destroys Movement
ALS doesn’t attack every part of the nervous system. It picks on two specific types of motor neurons: those in the brain (upper motor neurons) and those in the spinal cord (lower motor neurons). When these cells die, the brain can’t send signals to your muscles anymore. Your arms, legs, throat, and lungs slowly go quiet. You don’t lose your mind. You don’t lose your senses. You’re still fully aware, trapped inside a body that’s failing. That’s what makes ALS so cruel.
What kills these neurons? No one knows for sure. But one big clue is glutamate. Glutamate is a chemical in your brain that helps nerve cells talk to each other. Too much of it, and it becomes toxic. In ALS, glutamate builds up around motor neurons, overstimulating them until they burn out. This is called excitotoxicity. It’s like leaving a faucet running nonstop until the pipes burst.
Riluzole: The First Real Hope
In 1995, after decades of failed experiments, the FDA approved riluzole. It was the first drug ever approved to treat ALS. Before that, there was nothing. No slowing. No delay. Just decline.
Riluzole doesn’t fix the damage. It doesn’t bring back dead neurons. But it does something remarkable: it buys time. Clinical trials showed that people taking riluzole lived 2 to 3 months longer on average than those on placebo. That might sound small. But in a disease where death comes quickly, those extra months mean more birthdays, more conversations, more time with loved ones.
The drug works in three ways. First, it reduces the amount of glutamate released by nerve cells. Second, it blocks sodium channels on those cells, making them less likely to overfire. Third, it interferes with the signals that glutamate sends after it binds to receptors. Together, these actions calm the overactive nerve cells and protect them from self-destruction.
It’s not perfect. In one major study, 100mg per day reduced the risk of death or needing a breathing tube by 35%. A 200mg dose worked even better-but caused too many side effects. So 100mg daily became the standard: two 50mg pills, once in the morning and once at night.
How Riluzole Is Taken-and What Goes Wrong
Riluzole comes in three forms: tablets, oral suspension, and a thin film that dissolves on your tongue. The tablets (Rilutek) are the most common. But if swallowing is hard, the suspension (Tiglutik) or thin film (Exservan) can help.
Doctors usually start patients on 50mg once a day for a week, then bump it up to 50mg twice daily. Why? Because riluzole can hurt your liver. About 12% of people develop elevated liver enzymes. That’s why blood tests are required before starting and every month for the first three months. If liver numbers climb too high, the drug gets stopped.
Side effects are common. Nausea hits 25% of users. Diarrhea? 15%. Fatigue? 20%. Some people feel dizzy or weak. A few stop because it’s just too hard to live with. In one patient survey, 8% quit riluzole because of side effects. But 62% kept taking it-even with nausea-because they believed it gave them more time.
One Reddit user wrote: "Nausea was brutal the first 3 months. Now it’s manageable. My neurologist says my progression is slower than average. I’d take any chance for more time." Another shared: "My liver enzymes were 3x normal. I stopped. Frustrating when the only drug that might help damages your liver."
Who Benefits? Who Doesn’t?
Not everyone responds the same way. Some studies show riluzole extends life by 6 to 19 months. Others show no benefit at all. Why the difference? Real-world patients are more varied than clinical trial participants. Some have faster-progressing ALS. Others have slower forms. Some are younger. Others have other health problems.
The American Academy of Neurology gives riluzole a Level A recommendation-meaning it’s proven to work. But experts like Dr. Merit Cudkowicz say its mechanism is still "frustratingly opaque." We don’t fully understand how it works, and that makes it hard to predict who will benefit.
There’s also a big gap in access. In North America and Europe, 80-85% of newly diagnosed ALS patients start riluzole. But in low- and middle-income countries, only 15-20% can afford it. The cost isn’t just the drug-it’s the monitoring, the blood tests, the follow-ups. Without insurance or government support, many never even begin treatment.
What’s Next? New Forms, New Hope
Riluzole has been around for nearly 30 years. But it’s not standing still. In 2020, the FDA approved Exservan-an oral thin film that dissolves under the tongue. It’s absorbed faster, causes less stomach upset, and improves adherence. One trial showed 30% fewer gastrointestinal side effects compared to tablets.
Researchers are now testing riluzole in combination with other drugs. A trial at the University of Michigan is pairing it with sodium phenylbutyrate, hoping the two together offer stronger protection. Results are expected in 2024.
And while riluzole remains the most prescribed ALS drug globally, new therapies are entering the scene. Edaravone, approved in 2017, slows functional decline. Tofersen, approved in 2023, targets a specific genetic form of ALS (SOD1 mutations). These aren’t replacements for riluzole-they’re additions. For now, most patients still start with riluzole, then add others if they can.
Is Riluzole Worth It?
It’s not a miracle. It doesn’t reverse paralysis. It doesn’t stop the disease. But it does change the trajectory.
Think of it this way: ALS moves fast. Riluzole doesn’t slow the car-it just puts on the brakes a little. It’s not enough to stop the crash. But it might mean you reach your child’s graduation. Or hear your grandchild’s first word. Or have one more quiet morning with your partner.
That’s why, despite side effects, cost, and uncertainty, riluzole remains the foundation of ALS care. It’s the first line of defense. The only drug that’s been shown, again and again, to give people a few more months. In a disease with no cure, that’s not small. It’s everything.
